Neoadjuvant Chemotherapy in Retroperitoneal Sarcoma: A National Cohort Study.
Gabriella N TortorelloEric H LiCimarron E SharonKevin L MaRobert G MakiJohn T MiuraDouglas L FrakerRonald P DeMatteoGiorgos C KarakousisPublished in: Annals of surgical oncology (2023)
In patients undergoing surgical resection of RP LMS or DDLS, NCT does not appear to confer an OS advantage. Prospective randomized data from STRASS2 will confirm or refute these retrospective data.
Keyphrases
- neoadjuvant chemotherapy
- patients undergoing
- electronic health record
- locally advanced
- lymph node
- big data
- sentinel lymph node
- double blind
- open label
- cross sectional
- squamous cell carcinoma
- phase iii
- clinical trial
- quality improvement
- placebo controlled
- data analysis
- randomized controlled trial
- machine learning
- rectal cancer
- study protocol